Clinical Context
Peer-reviewed veterinary literature continues to shape everyday decision-making for canine patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.
What the Study Evaluated
A study published in Veterinary dermatology in 2026 evaluated fosmidomycin for the Treatment of Canine Otitis Externa: A Randomised, Double-Blinded, Controlled 'Split Body' Clinical Trial..
Key Findings
Targeted antimicrobial therapy for canine otitis externa (OE) represents an opportunity for antimicrobial stewardship. Fosmidomycin selectively inhibits the non-mevalonate pathway for isoprenoid biosynthesis utilised by canine-adapted, and not human-adapted, staphylococci. To evaluate the safety and efficacy of fosmidomycin for treatment of bacterial OE compared with enrofloxacin. Fifteen client-owned dogs with bilateral bacterial OE were enrolled. Fosmidomycin stability in solution for 28 days was confirmed before trial commencement. A 'split body' design was used: each ear canal was randomised to receive a solution of fosmidomycin or...
Why It Matters for Veterinary Professionals
For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for canine patients.
Practical Interpretation
The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.
Clinical Takeaway
Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.
Read the full article here.
List
Add
Please enter a comment